Italian Journal of Dermatology and Venereology最新文献

{"title":"Nail bed repair with dermal substitutes after excision of squamous cell carcinoma.","authors":"Davide Bertolla, Federico Tartari, Anna R Lombardi, Alessandro Borghi, Andrea Conti","doi":"10.23736/S2784-8671.26.08387-8","DOIUrl":"10.23736/S2784-8671.26.08387-8","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"292-293"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147355151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacoeconomic comparison of dupilumab and lebrikizumab for atopic dermatitis treatment in Italy: cost-per-responder analysis.","authors":"Paolo Gisondi, Massimiliano Povero, Luca Castello, Andrea Tassone, Maria P Pedone, Elena Nicoli, Kerry Noonan, Jules Tavi, Roberta DI Turi","doi":"10.23736/S2784-8671.26.08514-2","DOIUrl":"10.23736/S2784-8671.26.08514-2","url":null,"abstract":"<p><strong>Background: </strong>A cost per responder model was developed to compare the pharmacoeconomic value of dupilumab and lebrikizumab for the treatment of moderate-to-severe atopic dermatitis (AD) in Italy.</p><p><strong>Methods: </strong>Two indirect treatment comparisons were conducted at 16 and 52 weeks. In the 16-week analysis, dupilumab's efficacy was assessed against lebrikizumab (both with topical corticosteroids) using data from the LIBERTY AD CHRONOS and ADhere trials. The 52-week analysis, using LIBERTY AD SOLO-CONTINUE and ADvocate studies, focused on patients who achieved optimal response at 16 weeks (defined as ≥75% reduction in Eczema Area and Severity Index [EASI 75] and Investigator's Global Assessment of clear/almost clear skin score 0 or 1 [IGA 0/1]) to dupilumab or lebrikizumab. Responders were re-randomized to active treatment or placebo and followed until week 52. Treatment response was measured by EASI 75, Itch Numeric Rating Scale (I-NRS) ≥4, and IGA 0/1. The Number Needed to Treat (NNT) was calculated for each drug (vs. placebo) and multiplied by treatment cost to estimate the cost per additional responder.</p><p><strong>Results: </strong>At 16 weeks, dupilumab was more effective for all endpoints. Across all comparisons, dupilumab consistently demonstrated a lower NNT than lebrikizumab and its cost per responder was always more favorable with a delta cost of at least -€24,490 (for EASI 75). At 52 weeks, dupilumab remained more favorable in all outcomes with a difference in its cost per responder vs. lebrikizumab no less than -€28,649 (for IGA 0/1).</p><p><strong>Conclusions: </strong>This study suggests that dupilumab offers greater clinical and economic benefits than lebrikizumab for AD patients, supporting its preference among healthcare decision-makers.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"262-270"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148030541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Open-label, uncontrolled clinical investigation of the performance and safety of a foam containing a hyaluronic acid-derived biopolymer and humectants for management of dermatitis in adults.","authors":"Severino Persechino, Martina Manni, Silvia Innocenti, Francesca DI Vico, Adriana DI Guida, Luisa Abategiovanni, Alessandro Capalbo, Nazareno Gagliostro, Luca Ambrosio, Maddalena Napolitano","doi":"10.23736/S2784-8671.26.08303-9","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08303-9","url":null,"abstract":"<p><strong>Background: </strong>Atopic (AD) and contact (CD) dermatitis can interfere with everyday function. Non-prescription topical formulations can aid AD/CD symptom relief and alleviate exacerbation. In this post-marketing clinical investigation, performance and safety of a foam containing sodium butyroyl/formoyl hyaluronate, glycerol and panthenol was investigated.</p><p><strong>Methods: </strong>This multicenter, open-label, uncontrolled, post-marketing clinical follow-up investigation included 37 adults with mild-to-moderate AD, irritant CD (ICD) or allergic CD (ACD). The foam was applied twice-a-day to affected areas for 42 days and assessed on Days 14, 28 and 42 using the Investigators Global Assessment score (ICA; rated 0-5); the Eczema Area and Severity Index (EASI); the Dermatology Life Quality Index (DLQI); visual analogue scales (VAS) for pruritus, scratching, pain and burning; investigator's global evaluation of performance and participant overall treatment acceptability. Primary endpoint was IGA score change from baseline to Day 28. Success was prespecified as an IGA score decrease ≥1.</p><p><strong>Results: </strong>At Day 28, mean IGA score decreased from baseline by 1.11 (standard deviation 0.68) with treatment success in 88.6% of participants (P<0.0001). At Days 14/42, 52.8%/94.3% (P<0.0001) showed an improved IGA. Progressive improvements were shown in EASI, VAS and DLQI scores to Day 42, significant at each timepoint (P<0.001). For participant and investigator performance evaluation, 94.3% reported improvement. Most participants rated the foam's acceptability as \"very much satisfied\" or \"satisfied.\" The foam was generally well-tolerated.</p><p><strong>Conclusions: </strong>Use of a foam containing sodium butyroyl/formoyl hyaluronate, glycerol and panthenol led to significant alleviation of AD, ICD or ACD and decreased associated quality of life impacts.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148054314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of geographic tongue with adalimumab in a patient with psoriatic arthritis.","authors":"Alexandre R Meduri, Francesca Ferrante, Giulia Ciccarese, Francesca Ambrogio, Domenico Bonamonte, Paolo Romita, Caterina Foti","doi":"10.23736/S2784-8671.26.08576-2","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08576-2","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148042342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plantar basal cell carcinoma: a rare location.","authors":"Paolino Franzese, Andrea Ronchi, Giuseppe D'Abbronzo, Giuseppe Argenziano, Gabriella Brancaccio","doi":"10.23736/S2784-8671.26.08589-0","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08589-0","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148042328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bullous pemphigoid developing 25 years after pemphigus vulgaris: a rare case of possible epitope spreading.","authors":"Andrea Danese, Noemi Brigenti, Paolo Gisondi, Giampiero Girolomoni, Martina Maurelli","doi":"10.23736/S2784-8671.26.08409-4","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08409-4","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148042295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyaluronic acid fillers in the labiomental sulcus to reduce apparent chin prominence in class II hypodivergent patients: a retrospective clinical study.","authors":"Raffaele Rauso, Nicola Zerbinati","doi":"10.23736/S2784-8671.26.08626-3","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08626-3","url":null,"abstract":"<p><strong>Background: </strong>Hyaluronic acid (HA) fillers are commonly used for facial augmentation and contour enhancement, particularly to improve deficient skeletal projection. Their application to reduce the perceived prominence of the chin has not been previously reported. The aim is to describe indications, technique, safety, and aesthetic outcomes of HA filler injections into the labiomental crease for camouflage of apparent chin protrusion in selected patients.</p><p><strong>Methods: </strong>This retrospective study included 24 female patients with skeletal Class II hypodivergent profiles treated between 2019 and 2024. High-elastic modulus (G'>300 Pa) cross-linked HA fillers were injected intradermally into the labiomental sulcus using a linear retrograde threading technique. Clinical and photographic evaluations were performed at 1, 3, and 6 months. Patient satisfaction was assessed using a 10-point Visual Analog Scale (VAS).</p><p><strong>Results: </strong>All patients completed follow-up. Mild, transient erythema and edema occurred in all cases and resolved within 48 hours. Temporary blanching was observed in 12.5% of patients and resolved spontaneously. No severe or delayed adverse events were reported. Treatment resulted in consistent softening of the labiomental crease, an augmentation of the labiomental angle, and improved lower facial harmony. Mean VAS satisfaction score at 6 months was 8.7. In selected patients, results remained stable for up to 36 months.</p><p><strong>Conclusions: </strong>Labiomental crease injection with HA fillers is a safe, effective, and predictable minimally invasive technique to reduce perceived chin prominence in selected Class II hypodivergent patients, expanding the conceptual use of fillers beyond augmentation alone.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148042356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indicator conditions guide early HIV testing: an imperative for the Italian dermatology.","authors":"Massimo Giuliani, Maria C Fargnoli, Alessandra Latini","doi":"10.23736/S2784-8671.26.08347-7","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08347-7","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148030524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of RUVBL2 expression in malignant melanoma and its correlation with prognosis and immune infiltration.","authors":"Yigang Zhang, Mengru Gao, Xiangyu Qu, Lei Cui, Junjun Wu, Jiabin Deng","doi":"10.23736/S2784-8671.26.08523-3","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08523-3","url":null,"abstract":"<p><p>Cutaneous melanoma (SKCM) is a highly aggressive malignant tumor of the skin, characterized by rapid progression, strong metastatic potential, and poor clinical prognosis, which poses a serious threat to human health and imposes a heavy burden on global healthcare systems. Despite significant advances in therapeutic strategies such as targeted therapy and immunotherapy in recent years, the clinical outcomes of SKCM patients remain suboptimal, highlighting the urgent need to identify novel molecular biomarkers and therapeutic targets that can facilitate early diagnosis, accurate prognosis evaluation, and effective treatment of this disease. RUVBL2, a member of the AAA+ ATPase family, has been increasingly recognized as a key regulator in tumorigenesis and progression. Accumulating evidence from previous studies has demonstrated that RUVBL2 exerts oncogenic effects in multiple human malignancies. For instance, knockdown of RUVBL2 can inhibit cell proliferation, promote apoptosis, induce senescence, and suppress migration in hepatocellular carcinoma, and its high expression is closely associated with poor prognosis and chemoresistance. In colorectal cancer, RUVBL2 mRNA modified by m6A can be recognized and bound by YTHDF1 to enhance translation initiation and protein expression, and depletion of RUVBL2 impairs YTHDF1-driven oncogenic translation, leading to cell cycle arrest and apoptosis. Additionally, RUVBL2 has been shown to participate in the regulation of oncogenic signaling pathways, immune evasion, and therapeutic sensitivity in pancreatic cancer, bladder cancer, and breast cancer. However, the expression pattern of RUVBL2 in SKCM, its correlation with clinical prognosis and tumor immune microenvironment, as well as its potential functional role in SKCM progression, have not been fully elucidated to date. In view of the critical role of immune cell infiltration in the pathogenesis and progression of SKCM, and the clinical significance of immune checkpoint inhibitors (e.g., anti-PD-1 and anti-CTLA-4 agents) in SKCM treatment, exploring the association between RUVBL2 and tumor immune infiltration, as well as its predictive value for immunotherapeutic efficacy, is of great importance. Therefore, the present study aims to systematically investigate the expression level of RUVBL2 in SKCM and its correlation with clinical prognosis by integrating public database resources (TCGA, GTEx, and HPA) and in vitro experimental validation. Furthermore, we intend to explore the functional role of RUVBL2 in regulating SKCM cell proliferation, migration, invasion, and apoptosis, and clarify its association with immune cell infiltration and sensitivity to immunotherapy. The findings of this study are expected to provide a theoretical basis for the development of novel diagnostic markers and therapeutic strategies for SKCM.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148030552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective single-center study on efficacy and tolerability of ustekinumab biosimilars in moderate-to-severe psoriasis: short term results.","authors":"Antonella DI Cesare, Elia Rosi, Gian M Silvi, Anna L Marigliano, Francesca Prignano","doi":"10.23736/S2784-8671.26.08628-7","DOIUrl":"https://doi.org/10.23736/S2784-8671.26.08628-7","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148029332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}